John A. Gruner
Research Subjects
John A. Gruner has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Val R. Marcy
2 shared publicationsAndrew K Yee
1 shared publicationCaitlyn Benfield
1 shared publicationDonna Bozyczko-Coyne
Cephalon, Inc., West Chester, PA
1 shared publicationGreg Hostetler
1 shared publicationJoanne R. Mathiasen
1 shared publication
Latest Publications
- 1 November 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (21) , 6362-6365
Synthesis and evaluation of pyridazinone–phenethylamine derivatives as selective and orally bioavailable histamine H3 receptor antagonists with robust wake-promoting activity
- 1 November 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (21) , 6362-6365
Synthesis and evaluation of pyridazinone–phenethylamine derivatives as selective and orally bioavailable histamine H3 receptor antagonists with robust wake-promoting activity
- Open Access
- 1 November 2009
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 32 (11) , 1425-1438
The Roles of Dopamine Transport Inhibition and Dopamine Release Facilitation in Wake Enhancement and Rebound Hypersomnolence Induced by Dopaminergic Agents
Rebound hypersomnolence (RHS: increased sleep following increased wake) is a limiting side-effect of many wake-promoting agents. In particular, RHS in the first few hours following wake appears to be associated with dopamine (DA)-releasing agents, e.g., amphetamine, but whether it can also be produced by DA transporter (DAT) inhibition alone is unknown. In these studies, DA-releasing and DAT-inhibiting agents and their interaction were systematically examined for their ability to increase wake and induce RHS. Chronically implanted rats were evaluated in a blinded, pseudo-randomized design. 237 rats were used in these studies with 1 week between repeat tests. Animals were habituated overnight and dosed the next day, 5 h after lights on, with test agents. Sleep/wake activity and RHS were evaluated using EEG/EMG recording up to 22 h post dosing. In vitro dopamine release was evaluated in rat synaptosomes. At doses that produced equal increases in wake, DA-releasing (amphetamine, methamphetamine, phentermine) and several DAT-inhibiting agents (cocaine, bupropion, and methylphenidate) produced RHS during the first few hours after the onset of sleep recovery. However, other DAT-inhibiting agents (mazindol, nomifensine, GBR-12909, and GBR-12935) did not produce RHS. Combination treatment with amphetamine and nomifensine produced waking activity greater than the sum of their individual activities alone while ameliorating the amphetamine-like RHS. In rat synaptosomes, nomifensine reduced the potency of amphetamine to induce DA release ~270-fold, potentially explaining its action in ameliorating amphetamine-induced RHS. All DA releasing agents tested, and some DAT-inhibiting agents, produced RHS at equal wake-promoting doses. Thus amphetaminelike DA release appears sufficient for inducing RHS, but additional properties (pharmacologic and/or pharmacokinetic) evidently underlie RHS of other DAT inhibitors. Enhancing wake while mitigating RHS can be achieved by combining DAT-inhibiting and DA-releasing agents.
- 1 November 2009
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 32 (11) , 1425-1438
Open AccessThe Roles of Dopamine Transport Inhibition and Dopamine Release Facilitation in Wake Enhancement and Rebound Hypersomnolence Induced by Dopaminergic Agents
Rebound hypersomnolence (RHS: increased sleep following increased wake) is a limiting side-effect of many wake-promoting agents. In particular, RHS in the first few hours following wake appears to be associated with dopamine (DA)-releasing agents, e.g., amphetamine, but whether it can also be produced by DA transporter (DAT) inhibition alone is unknown. In these studies, DA-releasing and DAT-inhibiting agents and their interaction were systematically examined for their ability to increase wake and induce RHS. Chronically implanted rats were evaluated in a blinded, pseudo-randomized design. 237 rats were used in these studies with 1 week between repeat tests. Animals were habituated overnight and dosed the next day, 5 h after lights on, with test agents. Sleep/wake activity and RHS were evaluated using EEG/EMG recording up to 22 h post dosing. In vitro dopamine release was evaluated in rat synaptosomes. At doses that produced equal increases in wake, DA-releasing (amphetamine, methamphetamine, phentermine) and several DAT-inhibiting agents (cocaine, bupropion, and methylphenidate) produced RHS during the first few hours after the onset of sleep recovery. However, other DAT-inhibiting agents (mazindol, nomifensine, GBR-12909, and GBR-12935) did not produce RHS. Combination treatment with amphetamine and nomifensine produced waking activity greater than the sum of their individual activities alone while ameliorating the amphetamine-like RHS. In rat synaptosomes, nomifensine reduced the potency of amphetamine to induce DA release ~270-fold, potentially explaining its action in ameliorating amphetamine-induced RHS. All DA releasing agents tested, and some DAT-inhibiting agents, produced RHS at equal wake-promoting doses. Thus amphetaminelike DA release appears sufficient for inducing RHS, but additional properties (pharmacologic and/or pharmacokinetic) evidently underlie RHS of other DAT inhibitors. Enhancing wake while mitigating RHS can be achieved by combining DAT-inhibiting and DA-releasing agents.
- 1 January 1999
- Published by Elsevier in Brain Research
- Vol. 816 (2) , 446-456
4-Aminopyridine enhances motor evoked potentials following graded spinal cord compression injury in rats
- 1 January 1999
- Published by Elsevier in Brain Research
- Vol. 816 (2) , 446-456
4-Aminopyridine enhances motor evoked potentials following graded spinal cord compression injury in rats